New hope for rare immune disorder: long-term drug safety trial now recruiting
Disease control
Recruiting now
This study looks at the long-term safety of a drug called leniolisib for people with primary immunodeficiency disorders linked to PI3K signaling. It is for patients who were in a previous leniolisib study. The goal is to see if the drug remains safe and helps control immune probl…
Phase: PHASE2 • Sponsor: Pharming Technologies B.V. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC